In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 71 to 80 of 132

Sort by

Keyword or reference number: cancerRemove Keyword or reference number: cancer filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]	Technology appraisal guidance	4 November 2026
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance	28 January 2026
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]	Technology appraisal guidance	TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance	TBC
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]	Technology appraisal guidance	TBC

Results per page

10
25
50
All